Royal London Asset Management
INDV icon

Royal London Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Royal London Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,416
Closed -$571K – 651
2024
Q2 		$571K Sell
35,416
-434,429
-92% -$7.84M ﹤0.01% 643
2024
Q1 		$10.1M Buy
469,845
+22,017
+5% +$414K 0.03% 402
2023
Q4 		$6.84M Buy
447,828
+24,383
+6% +$433K 0.02% 474
2023
Q3 		$9.77M Sell
423,445
-26,595
-6% -$606K 0.03% 367
2023
Q2 		$10.7M Buy
+450,040
New +$10.3M 0.03% 352

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return

Royal London Asset Management's INDV Position: Q3 2024 in Review

Royal London Asset Management sold out of Indivior Pharmaceuticals (INDV) in Q3 2024, closing a stake of 35,416 shares — an estimated $571K sold.

Royal London Asset Management first reported a position in INDV in Q2 2023 and held it in 5 quarters. The position peaked at $10.7M in Q2 2023. 103 funds tracked by Wall St. Rank hold INDV as of Q3 2024.

  • Royal London Asset Management reported no remaining Indivior Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Royal London Asset Management sold 35,416 Indivior Pharmaceuticals shares in Q3 2024, an estimated $571K.
  • Royal London Asset Management first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Royal London Asset Management's Indivior Pharmaceuticals position peaked at $10.7M in Q2 2023.
  • 103 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2024.

Based on Royal London Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.